Close Menu

Veracyte

The firm said genomic testing volume rose 23 percent year over year, and raised its revenue guidance for full-year 2018.

The company's shares grew 28 percent in September after it terminated a licensing deal with BioMérieux and regained control of certain intellectual property.

Veracyte said that the draft policy is open to a 45-day comment period and could potentially go into effect in early 2019.

The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.

Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.

Veracyte anticipates that it can tap into the growing precision medicine market by leveraging its database of RNA sequencing data for thyroid and lung cancer. 

The firm will use the proceeds for working capital, but said it may also acquire or invest in complementary technologies or businesses.

The firm beat analysts' consensus estimates on both the top and bottom lines, and it raised its 2018 annual revenue guidance.

The study demonstrates that Veracyte's new test improves upon an earlier version in its ability to identify thyroid nodules that are likely to be benign.

Pages

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.